株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

遺伝子組み換えによる代用皮膚:治療法・市場・戦略・予測

Bioengineered Skin Substitutes to 2018 - Therapeutics, Markets, Strategies and Forecasts

発行 Greystone Research Associates 商品コード 240075
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
遺伝子組み換えによる代用皮膚:治療法・市場・戦略・予測 Bioengineered Skin Substitutes to 2018 - Therapeutics, Markets, Strategies and Forecasts
出版日: 2014年04月26日 ページ情報: 英文
概要

当レポートでは、遺伝子組み換えによる代用皮膚の市場について調査分析し、市場背景、代用皮膚の主要製品および技術の概要、治療区分別の市場機会の分析、事業化における各種課題、市場影響因子の分析、製品および技術の発展の見通しと市場規模の推移と予測、主要企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

先進遺伝子組み換え細胞市場のダイナミクス

  • 市場区分
    • 急性創傷
    • 慢性創傷・潰瘍
    • 手術創
    • 火傷
  • 市場と患者の人口動態
    • 市場力学
    • 成長阻害因子
  • 産業プロファイル
    • 産業構造
    • 競合環境
    • 技術市場の成長推進因子

遺伝子組み換え代用皮膚製品の分析

  • 無細胞基質
  • 同種異系基質
  • 同種異系シート
  • 二層化代用皮膚
  • 生吸収性スカフォールド
  • 細胞外基質(ECM)
  • コラーゲン生体膜
  • 異種グラフト
  • FDA未承認の代用皮膚

市場部門のデータ・評価・予測

  • 急性外傷
  • 火傷
  • 糖尿病性潰瘍
  • 圧迫性潰瘍
  • 静脈性潰瘍

ビジネス部門の戦略とリクス

  • 専用技術
  • 短期的な資本化
  • 戦略的アライアンス&提携
  • 開発ステージの移行要因
  • イネーブリング技術

市場影響因子

  • 治験要因
  • FDAガイドライン
  • 償還
  • 患者人口動態の変化
  • POC(ポイントオブケア)における処置
  • プロトコルとエンドポイント

関連事業者のプロファイル

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: ESK698F

Damage to skin tissue from refractory wounds, surgical procedures and injury represents a growing healthcare need. Shifting demographics will drive industry growth in the years ahead as an aging population provides further stimulus for tissue repair demand. Tissue engineering is now an emerging industry with research and development taking place in the world's leading universities and companies worldwide. Emerging products and processes for wound management and tissue repair include a number of synthetic and bioengineered products that have recently become available, or are being developed, as adjuncts to wound care and/or as a replacement for human skin.

Highlights

  • Analyzes and evaluates the new generation of tissue-engineered and biologically active technologies and products for replacing or augmenting damaged or diseased skin
  • Provides detailed analysis of bioengineered skin substitute products
  • Assesses business risk factors and market issues
  • Analyzes technology and product developments, and provides forecasts through 2018
  • Profiles bioengineered skin substitute companies, their product development activities, and strategies

What You Will Learn

  • What are the key segments and patient demographics that comprise the market for engineered skin substitutes?
  • What are the major therapeutic demand drivers for bioengineered skin substitutes?
  • What are the design factors, material selection issues and technologies that are being used in commercial and development-stage engineered skin substitute products?
  • What is the market share and product position in the market and what will it look like in 2018?
  • Who are the companies behind the current generation of bioengineered skin substitutes and what are their business models?
  • What is the role of pharma-device alliances and design partnerships in the commercialization and market access of new and emerging bioengineered skin substitutes?
  • What is the impact of economic, technology, and regulatory factors?

Table of Contents

Executive Summary

Advanced Bioengineered Tissue Market Dynamics

  • Market Segmentation
    • Acute Wounds
    • Chronic Wounds & Ulcers
    • Surgical Wounds
    • Burns
  • Market and Patient Demographics
    • Market Dynamics
    • Factors Limiting Growth
  • Industry Profile
    • Industry Structure
    • Competitive Landscape
    • Technology Market Drivers

Bioengineered Skin Substitute Product Analysis

  • Acellular Matrices
  • Allogeneic Matrices
  • Allogeneic Sheets
  • Bilayered Skin Substitutes
  • Bioabsorbable Scaffolds
  • Extracellular Matrix
  • Collagen Biomembranes
  • Xenografts
  • Non-FDA Cleared Skin Substitutes
    • Extracellular Matrices
    • Cultured Epidermal Autografts

Market Sector Data, Assessments & Forecasts

  • Acute Trauma
  • Burns
  • Diabetic Ulcers
  • Pressure Ulcers
  • Venous Ulcers

Business Sector Strategies and Risks

  • Proprietary Technology
  • Near-term Capitalization
  • Strategic Alliances & Partnerships
  • Development Stage Transition Factors
  • Enabling Technologies

Market Factors

  • Clinical Trial Factors
  • FDA Guidelines
  • Reimbursement
  • Evolving Patient Demographics
  • Point-of-Care Processing
  • Protocols and End-Points

Company Profiles

Back to Top